ClinicalTrials.gg
Not yet recruitingNCT07629570Updated Jun 5, 2026

A Clinical Trial of an Herbal Liquid Supplement - 'DBPS' for Managing Blood Pressure

An interventional study of DBPS and Placebo in Prehypertension, sponsored by Eetho Brands, Inc. Not yet recruiting at 4 sites in India. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Eetho Brands, Inc · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Prehypertension is a clinical condition characterized by systolic blood pressure (SBP) readings between 120 and 139 mmHg and/or diastolic blood pressure (DBP) readings between 80 and 89 mmHg, as per the Joint National Committee (JNC 7) and World Health Organization (WHO) guidelines. Individuals falling within this range do not yet meet the criteria for hypertension but are at a significantly elevated risk of progressing to full-blown hypertension and developing associated cardiovascular diseases such as heart attack and stroke. This stage is considered as a critical window for intervention, as timely and appropriate measures can potentially halt or delay the progression to more severe health issues.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effectiveness of 4-week supplementation regimen of 'DOSE for Blood Pressure Shot (DBPS)' in reducing systolic and diastolic blood pressure among prehypertensive adults. DBPS is formulated as a liquid oral supplement specifically designed to support cardiovascular wellbeing. The product is rooted in both preliminary scientific evidence and traditional medicinal practices, which indicate that it may exert blood-pressure lowering effects by influencing vascular tone and modulating inflammatory pathways within the body. The active ingredients in DBPS are believed to help relax blood vessels, improve endothelial function, and reduce systemic inflammation, all of which contribute to healthier blood pressure levels.

02

Conditions studied

  • Prehypertension

Keywords

  • Elevated Blood Pressure
03

In context

Prehypertension

158 studies on the registry are indexed under Prehypertension; 21 are open to participants now.

This study's planned enrollment of 198 is above the median of 66 across 138 interventional studies indexed under Prehypertension.

Browse Prehypertension studies →

Lead sponsor

Eetho Brands, Inc is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women between the ages 18 and 65 years, inclusive, at the time of signing the .
  2. Seated clinic systolic blood pressure (SBP) in the range of 120 to 139 mm Hg and diastolic blood pressure (DBP) in the range of 80 to 89 mmHg confirming a prehypertensive state as per JNC 7 and WHO guidelines.
  3. In good general health as determined by a medical history, physical examination, vital signs, (ECG), and routine clinical laboratory tests (hematology, clinical chemistry, urinalysis).
  4. less than 30 kg/m2.
  5. Women of (WOCBP) must agree to use a highly effective method of (e.g., oral contraceptives, intrauterine device, barrier methods with spermicide, surgical sterilization) from screening until the end of the study. Women who are (defined as amenorrhea for at least 12 consecutive months) or surgically sterile are eligible.
  6. Provide written informed consent to participate in the study after all procedures have been fully explained and questions answered.
  7. Willing and able to comply with all study procedures, visit schedules, and restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with Stage 1 Hypertension (SBP more than 139 mmHg or DBP more than 89 mmHg or Stage 2 Hypertension as per JNC 7 and WHO guidelines
  2. Evidence of secondary hypertension (e.g., renal artery stenosis, primary hyperaldosteronism, sleep apnea).
  3. History of significant cardiovascular disease, including but not limited to:

    (i) Myocardial infarction, stroke, or within the past 6 months.

    (ii) Symptomatic heart failure or less than 40%.

    (iii) Cases of class III and class IV congestive heart failure (CHF) as defined by the .

    (iv) Unstable angina pectoris or revascularization procedure within the past 3 months.

    (v) Significant valvular heart disease or complex congenital heart disease by medical history.

  4. Use of any medications (prescription, over-the-counter, herbal supplements, certain vitamins/minerals) known to affect blood pressure or interfere with study product absorption/metabolism within 14 days prior to the dosing visit, or unwillingness to stop them for the study duration.
  5. Organ Function Impairment:

    (i)Impaired hepatic function ( [ALT] or Aspartate aminotransferase more tan 2 times the [ULN]).

    (ii)Impaired renal function (serum creatinine level more than 132.6 μmol/L or estimated [eGFR] less than 60 mL/min/1.73m2).

    (iii) Serum potassium outside the normal range (less than 3.5 mmol/L or more than 5.5 mmol/L).

  6. History of uncontrolled diabetes mellitus (e.g., level more than 7.0% and/or FBS more than 125mg/dL or use of diabetes medications).
  7. Any chronic diseases that may interfere with study participation or pose additional risk to the subject.
  8. A tobacco smoker or user of nicotine products in the 6 months prior to screening.
  9. Excessive alcohol consumption (Men more than 14 drinks/week and women more than 7 drinks/week).
  10. History of substance abuse or dependency within the last 1 year.
  11. Women who are pregnant or lactating.
  12. History of or to the test product (DBPS) or any of its components or placebo.
  13. Participation in another clinical research study involving an product within 30 days prior to screening or during the current study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    DBPS- Double dose

    DOSE for Blood Pressure Shot (DBPS)-A proprietary oral liquid supplement formulation containing active and inactive ingredients of herbal and natural extracts.

    Dietary Supplement: DBPS

  • Experimental
    DBPS -Single dose

    DOSE for Blood Pressure Shot (DBPS)-A proprietary oral liquid supplement formulation containing active and inactive ingredients of herbal and natural extracts.

    Dietary Supplement: DBPS

  • Placebo comparator
    Comparator

    An oral liquid supplement formulation similar to the proprietary formulation but with no active ingredients.

    Other: Placebo

Interventions

  • Dietary supplementDBPS

    DOSE for Blood Pressure Shot (DBPS)-A proprietary oral liquid supplement formulation containing active and inactive ingredients of herbal and natural extracts.

  • OtherPlacebo

    An oral liquid supplement formulation similar to the proprietary formulation but with no active ingredients.

06

What researchers measure

Primary outcomes

  1. Systolic Blood Pressure

    Change from baseline to end of the study (4 weeks) in the readings of Systolic Blood Pressure.

    Time frame: Week 0 & Week 4

Secondary outcomes

  1. Diastolic Blood Pressure (DBP)

    Change from baseline to end of the study (4 weeks) in the readings of Diastolic Blood Pressure.

    Time frame: Week 0 & Week 4

  2. Systolic and Diastolic Blood Pressure (SBP and DBP) as recorded by a twenty- four hour-ambulatory blood pressure monitor (24hr ABPM)

    Change from baseline to end of the study (4 weeks) in the readings of Systolic and Diastolic Blood Pressure (SBP and DBP) as recorded by a twenty- four hour-ambulatory blood pressure monitor (24hr ABPM)

    Time frame: Week 0 & Week 4

  3. hsCRP level

    Change from baseline to end of the study (4 weeks) in the level of hsCRP biomarker in serum.

    Time frame: Week 0 & Week 4

07

Study locations

4 sites
  • Trimurti Hospital
    Varanasi, Uttar Pradesh 221002, India
    • Dr. Ram Murti Singh, MD · Contactram.trimurti@gmail.com · +91-9415221720
    • Dr Ram Murti Singh, MD · Principal investigator
  • Jain Clinic
    Varanasi, Uttar Pradesh 221003 ,, India
    • Dr. Harshit Jain, MD · Contactharsh656@gmail.com · +91-9793036567
    • Dr Harshit Jain, MD · Principal investigator
  • Kashi Medicare
    Varanasi, Uttar Pradesh 221007, India
    • Dr Manoj Kumar Srivastava Srivastava, MD · Contactmanojsrivastava39@yahoo.in · +91-0542-2281750
    • Dr Manoj Kumar Srivastava, MD · Principal investigator
  • Octavia Hospital
    Varanasi, Uttar Pradesh, India
    • Dr Raghvendra Kumar Singh, MD · Contactraghvendras069@gmail.com · +91-8765548689
    • Dr Raghvendra Kumar Singh, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jul 2026, 2 months later.

Of 60 interventional studies with no phase under Prehypertension, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
Jun 5, 2026
StartEst.
May 15, 2026
Primary completionEst.
Jul 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07629570
Lead sponsor
Eetho Brands, Inc
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
May 15, 2026 (estimated)
Primary completion
Jul 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Jun 5, 2026

Study contacts

Dr Manoj Kumar Srivastava, MD
Contact
manojsrivastava39@yahoo.in
+91-0542-2281750

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion